Hbm Pharma S.r.o.

What Hbm Pharma S.r.o. does

HBM Pharma s.r.o. is a Slovak-headquartered contract manufacturing organization (CMO) that produces sterile pharmaceutical injectables in ampoules (1–10 ml) via terminal sterilization and aseptic filling, and manufactures film-coated and sugar-coated tablets. Founded in 1992 as the Hoechst-Biotika joint venture, the company has operated GMP-certified production in Martin, Slovakia since 1994 (tablets) and 1996 (ampoules on an isolator filling line), and was acquired by Lithuanian pharmaceutical group Sanitas in 2005 before rebranding to HBM Pharma in 2010.

The firm's integrated offering spans contract manufacturing, contract packaging (Alu-Alu and PVC-Alu blistering with serialization for EU and Russian markets), applied analytical services, co-development of registration dossiers, qualification and validation, and storage with 2,500 pallet places of warehousing. Annual manufacturing capacity is 130 million ampoules and 600 million tablets. In-house quality control and batch release complete the full-service CMO proposition.

HBM Pharma operates a B2B enterprise model, generating revenue through long-term contract manufacturing relationships with branded and generic pharmaceutical companies across Europe. Its customer base includes TEVA/Ratiopharm, Stada, Egis, Hameln, Grindeks, PannonPharma, and Wörwag Pharma, among others. The company reports annual sales exceeding EUR 40 million and employs more than 370 people, accessing clients through direct enterprise engagement rather than public marketing channels.

Name

Hbm Pharma S.r.o.

Legal name

HBM Pharma s.r.o.

Website

https://hbmpharma.eu

Company type

Private

Founded year

1992

Operating status

Operating

Short description

HBM Pharma s.r.o. is a Slovak pharmaceutical contract manufacturer producing sterile injectables in ampoules and film- or sugar-coated tablets, plus packaging, analytical, and validation services for European pharma companies, reporting over EUR 40M in annual sales.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

Keywords

• Pharmaceutical contract manufacturing
• Sterile injectable manufacturing
• Tablet contract manufacturing
• Ampoule filling services
• GMP pharmaceutical outsourcing

Headquarters

HQ city

Martin

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Contract Manufacturing Services: HBM Pharma generates revenue primarily through contract manufacturing of pharmaceutical products including injectables in ampoules and tablets. The company operates as a full-service provider offering manufacturing, packaging, analytical services, dossiers, validation, and storage. Revenue is derived from long-term contractual relationships with pharmaceutical companies.
2. Contract Packaging Services: Secondary revenue from contract packaging of pharmaceutical products including ampoules and tablets. Services include Alu-Alu and PVC-Alu packaging, serialized packaging for EU market, and serialized and aggregated packaging for Russian market.
3. Analytical and Validation Services: Applied analytical services, co-development of registration dossiers, and qualification and validation services for pharmaceutical manufacturing.
4. Storage and Warehousing: Storage services utilizing 2,500 pallet place warehousing capacity for pharmaceutical products.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

HBM Pharma s.r.o. is a pharmaceutical Contract Manufacturing Organization (CMO) that produces sterile injectables in ampoules (1–10 ml) using both terminal sterilization and aseptic filling, and bulk tablets including film- and sugar-coated forms, for European pharmaceutical clients. It also provides full-service support including contract packaging with EU and Russian serialization, in-house analytical services, quality control and batch release, co-development of registration dossiers, qualification and validation, and pharmaceutical warehousing with 2,500 pallet places.

Product overview

HBM Pharma s.r.o. is a Contract Manufacturing Organization (CMO) offering a comprehensive portfolio of pharmaceutical manufacturing services. The core offerings include production of sterile injectables in ampoules (1-10 ml) using terminal sterilization and aseptic filling, and production of bulk tablets (film and sugar coated). These are supplemented by packaging services with serialization capabilities for both EU and Russian markets, quality control and batch release, analytical services, co-development of registration dossiers, qualification and validation, and storage. The company positions itself as a full-service provider for the pharmaceutical business with lean and flexible solutions.

Differentiator

Problem solved

Functional benefit

Products and services

• Sterile Injectables in Ampoules Contract Manufacturing Contract manufacturing of sterile injectable solutions in 1–10 ml ampoules using both terminal sterilization and aseptic filling on an isolator filling line, for pharmaceutical clients requiring GMP-certified sterile production.
• Bulk Tablet Production Contract manufacturing of bulk tablets including film-coated and sugar-coated tablets for pharmaceutical customers.
• Contract Packaging of Ampoules and Tablets Secondary packaging services for ampoules and tablets including Alu-Alu and PVC-Alu blister packaging formats.
• Serialized Packaging for EU Market Contract packaging of ampoules and tablets with serialization compliant with the EU Falsified Medicines Directive.
• Serialized and Aggregated Packaging for Russian Market Contract packaging of ampoules with serialization and aggregation complying with Russian drug-tracking requirements.
• Quality Control and Batch Release In-house analytical quality control services for pharmaceutical products manufactured at the facility, including complete batch release.
• Applied Analytical Services Analytical testing and quality assurance services for pharmaceutical products.
• Registration Dossier Co-Development Co-development of registration dossiers and regulatory support for pharmaceutical products manufactured at the site.
• Qualification and Validation Services Qualification and validation services for pharmaceutical manufacturing processes, equipment, and facilities.
• Storage and Warehousing Pharmaceutical product warehousing and storage services utilizing 2,500 pallet places.

Quantifiable outcome

• 130 million ampoules annual manufacturing capacity
• +3 more outcomes

Named customers10 records

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• GrindekscoreStrategic or Co-development Partner · 1 July 2010Grindeks, a Latvian pharmaceutical company, entered into a strategic partnership with HBM Pharma in July 2010. This partnership is significant as Grindeks is also listed as a reference customer, indicating both a strategic and commercial relationship. The partnership enhanced HBM Pharma's network in the Baltic and Eastern European pharmaceutical markets.
• SanitascoreStrategic or Co-development Partner · 1 July 2005Sanitas, a Lithuanian pharmaceutical company, acquired HBM Pharma in July 2005. This acquisition established the ownership structure of HBM Pharma, positioning it within the Sanitas Group of pharmaceutical companies.

Scale indicators6 records

Recent moves6 records

Expansion highlights3 records

Direct peers

• Recipharm: Recipharm is a European CDMO offering sterile fill-finish, solid dose manufacturing, and packaging services to pharma companies. Directly comparable to HBM Pharma in business model (contract manufacturing of injectables and tablets), customer base (generic and specialty pharma), and geographic focus (Europe).
• Aenova: Aenova is a leading European CDMO providing solid, semi-solid, and sterile dosage form manufacturing as well as packaging. Comparable to HBM in offering both injectables and tablet production under a CMO model for pharma customers across Europe.
• Haupt Pharma: Haupt Pharma is a European CDMO focused on sterile injectables (ampoules and vials), tablets, and contract manufacturing services. A direct competitor to HBM Pharma in small-molecule sterile fill-finish and solid dose contract manufacturing.
• Fareva: Fareva is a European pharmaceutical CDMO operating multiple manufacturing sites across Europe, offering sterile, liquid, and solid dosage forms as well as packaging. Directly comparable to HBM in serving pharma customers with contract manufacturing and serialization capabilities.
• CordenPharma: CordenPharma is a full-service CDMO offering API and drug product manufacturing including sterile injectables and oral solids. Comparable to HBM Pharma as a contract manufacturer serving pharmaceutical companies with injectable and tablet production.
• Siegfried Holding: Siegfried is a Swiss CDMO manufacturing APIs and finished dosage forms including sterile injectables and tablets. Comparable to HBM in providing contract manufacturing services to pharmaceutical companies across Europe with regulatory-grade production.

Broad incumbents

• Piramal Pharma Solutions: Piramal Pharma Solutions is a large global CDMO offering sterile injectables fill-finish, oral solids, and integrated drug substance/drug product services. Operates broadly in the same CDMO space as HBM Pharma but at significantly larger scale and global reach.
• Catalent: Catalent (now under Novo Holdings) is one of the largest global CDMOs with extensive sterile fill-finish and softgel/oral solid capabilities. A broad incumbent in the CDMO space competing for the same pharma clients as HBM Pharma, but at significantly greater scale and geographic reach.

Others

• Grindeks: Grindeks is a Latvian pharmaceutical manufacturer that has had a strategic partnership with HBM Pharma since 2010 and is also a reference customer. Not a direct competitor but a closely linked pharmaceutical manufacturer relying on HBM for contract manufacturing capacity.
• Sanitas (parent): Sanitas is a Lithuanian pharmaceutical manufacturer that has owned HBM Pharma since 2005 and uses HBM for contract manufacturing. Not a direct competitor but a strategic shareholder and adjacent pharmaceutical manufacturer with which HBM has deep commercial ties.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks1 record

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/hbm-pharma-s-r-o

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hbm Pharma S.r.o.